184 related articles for article (PubMed ID: 31824191)
1. Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease.
Wang QY; Li Y; Liang ZY; Yin Y; Liu W; Wang Q; Dong YJ; Sun YH; Xu WL; Ren HY
Cancer Manag Res; 2019; 11():10195-10203. PubMed ID: 31824191
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
[TBL] [Abstract][Full Text] [Related]
3. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].
Liu J; Cao YG; Zhang RL; Zhai WH; Chen X; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):472-478. PubMed ID: 37550202
[No Abstract] [Full Text] [Related]
4. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
5. Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation.
Zhu J; Wang Q; Ren H; Dong Y; Yin Y; Wang Q; Liang Z; Liu W; Wang Q; Wang B; Li Y
Front Immunol; 2023; 14():1274492. PubMed ID: 37928518
[TBL] [Abstract][Full Text] [Related]
6. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
Zhao XL; Jiang EL; Zhai WH; Ma QL; Pang AM; Wei JL; He Y; Yang DL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):467-471. PubMed ID: 31340618
[No Abstract] [Full Text] [Related]
7. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
Cao YG; He Y; Zhang SD; Liu ZX; Zhai WH; Ma QL; Pang AM; Wei JL; Yang DL; Huang Y; Feng SZ; Jiang EL; Han MZ
Biol Blood Marrow Transplant; 2020 Feb; 26(2):285-291. PubMed ID: 31494229
[TBL] [Abstract][Full Text] [Related]
8. [Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
Yuan J; Ren H; Qiu Z; Li Y; Wang M; Liu W; Xu W; Sun Y; Wang L; Liang Z; Dong Y; Ou J; Wang W; Yin Y; Cen X; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):475-9. PubMed ID: 26134011
[TBL] [Abstract][Full Text] [Related]
9. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
11. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
12. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
13. Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
Zheng X; Gao H; Lu N; Wang M; Zhang H; Zheng Y; Shen B; Cao Y; Chen X; Zhai W; Wei J; Yang D; Zhang R; Pang A; Feng S; Jiang E; Han M
Ann Hematol; 2023 Dec; 102(12):3603-3611. PubMed ID: 37878011
[TBL] [Abstract][Full Text] [Related]
14. Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
D'Angelo CR; Hall A; Woo KM; Kim K; Longo W; Hematti P; Callander N; Kenkre VP; Mattison R; Juckett M
Leuk Res; 2020 Sep; 96():106419. PubMed ID: 32683127
[TBL] [Abstract][Full Text] [Related]
15. [Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
Zheng H; Wang J; Zhou J; Wang P; Fu C; Wu D; Sun A; Qiu H; Jin Z; Han Y; Tang X; Ma X
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):121-4. PubMed ID: 25778887
[TBL] [Abstract][Full Text] [Related]
16. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
Ren Y; Liu F; Chen X; Zhang X; Zhao B; Wan Y; Lan Y; Li X; Yang W; Zhu X; Guo Y
Ann Hematol; 2024 Apr; 103(4):1345-1351. PubMed ID: 38316642
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
18. Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
Yao W; Chu X; Fang X; Zhu X; Tang B; Wan X; Geng L; Tong J; Song K; Zhang X; Qiang P; Sun G; Liu H; Sun Z
J Clin Pharm Ther; 2020 Dec; 45(6):1372-1381. PubMed ID: 33010180
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study.
Wang Y; Sun Y; Xie J; Hu J; Liu N; Chen J; Li B; Lan S; Niu J; Wang L; Qiao Z; Zhang Y; Ren J; Zhang B; Qian L; Tan Y; Dou L; Li Y; Hu L
Front Oncol; 2022; 12():928324. PubMed ID: 35924157
[TBL] [Abstract][Full Text] [Related]
20. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
